ATLANTA, GA – – (Globe Newswire – March 31, 2026) – – A shareholder class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra”) (NASDAQ: ALDX). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Aldeyra’s business, operations, and prospects, including allegations that: (1) the results of the reproxalap clinical trials were inconsistent; and (2) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful.

If you purchased Aldeyra shares between November 3, 2023 and March 16, 2026, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/aldeyra-therapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is May 29, 2026.